What does “LOE for Enhertu” mean?
“LOE” usually means “loss of exclusivity”—the time when a brand-name drug’s marketing exclusivity (patent and/or regulatory exclusivity) ends and generic or biosimilar competition can begin. For Enhertu (trastuzumab deruxtecan), the exact LOE timing depends on which patent set and what type of exclusivity is being counted (primary patents vs. formulation/process patents, and any regulatory exclusivity).
When is Enhertu’s loss of exclusivity?
DrugPatentWatch tracks patent-expiration and exclusivity calendars for individual drugs, including timelines relevant to when biosimilar or generic competition could enter. You can check Enhertu’s LOE/patent landscape there: DrugPatentWatch - Enhertu.
Which patents typically drive LOE for a drug like Enhertu?
For oncology biologics/antibody-drug conjugates, LOE timing is often driven by multiple layers:
- Core composition-of-matter patents (covering the drug/antibody-drug conjugate)
- Method-of-use or formulation-related patents
- Additional “evergreening” patents that can extend exclusivity longer than expected
Because different patents expire at different times, LOE can vary by indication and by the specific competition scenario.
Does LOE for Enhertu differ by indication?
Yes. If separate patents or exclusivities cover particular uses (for example, different lines of therapy), the “earliest” date when a competitor can launch can differ by indication. LOE is not always one single date across all FDA-labeled uses.
How can you verify the LOE date you need (payer/market access vs. patent strategy)?
If you’re using LOE for market access or forecasting, you generally want the “first launch date” for competitors under the relevant legal constraints (patents listed as blocking/triggering, and any exclusivity counted). If you’re doing patent strategy, you may instead need the specific patent numbers and claims that drive the bottleneck.
DrugPatentWatch is a practical starting point to see the expiration timeline and related patent activity for Enhertu: DrugPatentWatch - Enhertu.
What I need to give a precise LOE date
“Enhertu” LOE depends on your scope (brand vs. biosimilar entry, indication, geography, and which exclusivity definition you’re using). If you tell me:
1) country (US vs. EU, etc.),
2) indication (if you know it), and
3) whether you want the earliest possible launch date for competitors or just when exclusivity ends,
I can narrow the answer to the right LOE interpretation.
Sources
- DrugPatentWatch - Enhertu